Evidence map›Paper›PMID 17022621›Full record

ReviewJournal of proteome research2006

Nanotools for megaproblems: probing protein misfolding diseases using nanomedicine modus operandi.

Vladimir N Uversky, Alexander V Kabanov, Yuri L Lyubchenko

Open access · greenAbstract readReview
In one paragraph

Review in Journal of proteome research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Effect of electrostatics on aggregation of prion protein Sup35 peptide.Journal of physics. Condensed matter : an Institute of Physics journal · 2012
    Article
  3. Article
  4. Article
  5. Early stages for Parkinson's development: alpha-synuclein misfolding and aggregation.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2009
    Article
  6. Protein folding: are we there yet?Archives of biochemistry and biophysics · 2008
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Vladimir N UverskyCenter for Computational Biology and Bioinformatics, Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA. vuversky@iupui.edu
Alexander V Kabanov
Yuri L Lyubchenko
Institute for Biological Instrumentation · RU

Funding

Polypeptide Modification for Enhanced Brain DeliveryR01NS051334 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BANKS, WILLIAM A, KABANOV, ALEXANDER V · 2006 to 2014
$2.7M
INTERACTIONS OF BLOCK COPOLYMERS IN BLOOD BRAIN BARRIERSR01NS036229 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KABANOV, ALEXANDER V · 1997 to 2006
$1.9M
LOCAL AND GLOBAL STRUCTURES OF SUPERCOILED DNAR01GM062235 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI LYUBCHENKO, YURI L · 2001 to 2007
$1.7M
Nanomedicine Center for Protein Deposition Diseases(RMI)PN1EY016593 · NEI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI LYUBCHENKO, YURI L · 2004 to 2004
$74k
NEI NIH HHS 1-PN1 EY016593NEI NIH HHS PN1 EY016593NIGMS NIH HHS GM62235NIGMS NIH HHS R01 GM062235NINDS NIH HHS NS051335NINDS NIH HHS NS36229NINDS NIH HHS R01 NS036229NINDS NIH HHS R01 NS051334
6 · The paper itself

Abstract

Misfolding and self-assembly of proteins in nanoaggregates of different sizes and morphologies (nanoensembles, primary nanofilaments, nanorings, filaments, protofibrils, fibrils, etc.) is a common theme unifying a number of human pathologies termed protein misfolding diseases. Recent studies highlight increasing recognition of the public health importance of protein misfolding diseases, including various neurodegenerative disorders and amyloidoses. It is understood now that the first essential elements in the vast majority of neurodegenerative processes are misfolded and aggregated proteins. Altogether, the accumulation of abnormal protein nanoensembles exerts toxicity by disrupting intracellular transport, overwhelming protein degradation pathways, and/or disturbing vital cell functions. In addition, the formation of inclusion bodies is known to represent a major problem in the production of recombinant therapeutic proteins. Formulation of these therapeutic proteins into delivery systems and their in vivo delivery are often complicated by protein association. Thus, protein folding abnormalities and subsequent events underlie a multitude of human pathologies and difficulties with protein therapeutic applications. The field of medicine therefore can be greatly advanced by establishing a fundamental understanding of key factors leading to misfolding and self-assembly responsible for various protein folding pathologies. This article overviews protein misfolding diseases and outlines some novel and advanced nanotechnologies, including nanoimaging techniques, nanotoolboxes and nanocontainers, complemented by appropriate ensemble techniques, all focused on the ultimate goal to establish etiology and to diagnose, prevent, and cure these devastating disorders.

Indexed as

AmyloidosisHumansNanomedicineNanotechnologyNeurodegenerative DiseasesProtein Folding

Identifiers

PMID17022621
PMCPMC1880889
OpenAlexW2063313827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.